New drug combo shows promise for rare, aggressive blood cancer

This study tests whether adding the immunotherapy drug sintilimab to standard chemotherapy can help people with a rare and aggressive type of lymphoma (NK/T-cell lymphoma) that has spread. About 84 newly diagnosed patients will be randomly assigned to receive either the combination or chemotherapy alone. The goal is to see if the combination delays cancer growth and is safe.